Philadelphia biotech firm raises $14.2M to advance potential Parkinson's disease therapy

The company's goal is to be the first to develop a drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative diseases.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.